Items Tagged ‘checkpoint inhibitor’

July 18th, 2017

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma

By

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in patients receiving Opdivo compared to Yervoy. There remains an unmet need for additional treatment options for individuals with stage III and resected stage IV high-risk melanoma […]

View full entry

Tags: adjuvant therapy, checkmate-238, checkpoint inhibitor, Melanoma, News, nivolumab, opdivo, PD-1, Precision Cancer Medicine


June 22nd, 2017

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

By

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, durvalumab, immunotherapy, News, precision medicine, Triple Negative Breast Cancer


June 15th, 2017

With Nearly Three Years of Follow-Up, Keytruda® Continues to have Improved Survival Benefit Compared to Yervoy® in Advanced Melanoma

By

Keytruda® (pembrolizumab) continues to outperform Yervoy® (ipilimumab) as initial treatment of patients with advanced melanoma. Updated results of the KEYNOTE 006 trial presented at the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) report that Keytruda is now associated with a 30% improvement in survival when used as initial treatment for advanced […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, ipilimumab, KEYNOTE-006, keytruda, Melanoma, News, PD-1, pembrolizumab, precison medicine, Yervoy


June 9th, 2017

Shows Improved Outcomes with Addition of Keytruda® in Triple Negative High-Risk Breast Cancer

By

The results from the I-SPY 2 TRIAL investigating Keyytruda (pembrolizumab), in combination with standard therapy as a pre-operative (neoadjuvant) treatment for patients with locally advanced breast cancer were released at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.  The estimated pathologic complete response (pCR) rate increased nearly threefold in patients with triple-negative […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, keytruda, News, opdivo, PD-1, precision medicine, Triple negative Breast Cancer (TNBC), Yervoy